AQI Certified Centers AQI Certified Centers, recognized and certified for providing excellence in Alzheimer's care. 3) Ray Dolby Brain Health Center Sutter Health 45 Castro Street, Suite 220 San Francisco, CA 94114

Certified Sites This link will get you to a map of the sites Abington Neurological Associates Dr. David Weisman 1151 Old York Rd, Suite 200 Abington, PA 19001 Aventura Neurologic Associates, LLC Dr. Julie Schwartzbard 21000 NE 28th Avenue, Suite 205 Aventura, FL 33180 Baptist Health: Marcus Neuroscience Dr. Gediminas Gliebus 670 Glades Road, Suite 300 Boca Raton, FL 33431 Baptist Health: North Little Rock Dr. Mark Pippenger 3401 Springhill Drive, Suite 490-A North Little Rock, Arkansas 72117 Barrow Neurological Institute Drs. Anna Burke, Marwan Sabbagh, Tom Finkelstein 240 W Thomas Rd, Phoenix, AZ 85013 Baylor University Drs. Cindy Marshall & Claudia Padilla 9101 N Central Expy, Dallas, TX 75225 Brain and Spine Center Dr. Hermant Pandey 4045 W Chandler Blvd, Bldg F, Chandler, AZ 85226 BrainLove Dr. Dani Cabral 801 W. Maryland Ave Phoenix, AZ 85013 Bristol Health Dr. Margarita Reyes 85 Beleden Gardens Dr Bristol, CT 06010 Broadlawns Medical Center Dr. Yogesh Shah 1801 Hickman Road Des Moines , 50314 Central Wyoming Neurology Michele Belveal 5820 E 2nd St, Casper, WY 82609 Colorado Neurological Clinic Dr. Adam Wolff 950 East Harvard Avenue, Suite 570 Denver, CO 80210 Georgetown University Dr. Raymond Turner 4000 Reservoir Road, NW Washington, DC 20057 Greater Milford Neurology Dr. Lisa Dayaw 327 West St Milford, MA 01757 Hattiesburg Clinic Dr. Ronald L. Schwartz 415 S. 28th Ave. 6th Floor Hattiesburg, MS 39401 Indiana University Dr. Jared Brosc h 355 W. 15th St., Suite 3200 Indianapolis, IN 46202 Kootenai Health Dr. Susan Melchiore, 1919 Lincoln Way, #110 Coeur d'Alene, ID 83814 Maine Health Dr. Jeffery Maneval 92 Campus Dr. Ste. B, Scarborough, ME, 04074 Memorial Healthcare Dr. Cara Leahy 819 North Shiawassee St 1st Floor, Owosso, MI 48867 MercyOne Genesis Dr. Kayla Ehrman 1351 W. Central Park Ave, Pavilion 1, STE 340 Davenport, IA 52804 Michigan Institute for Neurological Disorders Dr. Jonathan Fellows 28595 Orchard Lake Road • Ste 200 Farmington Hills, MI 48334 Missouri Memory Center Dr. Curtis P. Schreiber 1245 N Butterfield Rd suite c1, Bolivar, MO 65613 NeuroCare Center Dr. Ryan Drake 4048 Dressler Rd NW, Canton, OH 44718 Neurology Cente r of New England, PC Dr. Salvatore Napoli 9 Payson Rd Foxborough, MA 02035 The Neuron Clinic Dr. Jose Soria 838 Nordahl Rd, # 200, San Marcos, CA 92069 Northwell – Hofstra - Feinstein Dr. Luca Giliberto 611 Northern Blvd #150, Great Neck, NY 11021 Northwestern University Dr. Joshua G. Cahan 420 E. Superior St. Chicago, IL 60611 Norton Neuroscience Institute Dr. Gregory E Cooper 4915 Norton Healthcare Boulevard, #301 Louisville, KY 40241 Ohio State University Dr. Doug Scharre 6100 N Hamilton Rd, Westerville, OH 43081 Stanford Center for Memory Disorders Dr. Sharon Sha 453 Quarry Road, MC 5979 Palo Alto, CA 94304 Southern Neurology Dr. Raymond Schwartz 10 / 11 Kensington St Kogarah NSW 2217 Specialist Memory Services Dr. James Bice 1/935 Station St Box Hill North, 3129 SUNY Upstate Neurodegenerative Disorders Center Dr. Tinatin Chabrashvili 90 Presidential Plaza, Syracuse, NY, 13210 Sutter Health: Ray Dolby Brain Health Center Dr. Armen Moughamian 45 Castro St #220 San Francisco, CA 94114 Tallaght University Drs. Sean Kennelly, Aoife Fallon, Antoinette Oconnor, Sean O Dowd Tallaght University Hospital, Tallaght, Dublin 24, D24 NR0A Tokyo Metropolitan Institute for Geriatrics Dr. Atsushi Iwata 35-2 Sakae-cho,Itabashi-ku, Tokyo, 173-0015,Japan Toronto Memory Program Dr. Sharon Cohen 1 Valleybrook Dr, North York, ON M3B 2S7, Canada University Hospitals Cleveland Medical Center Dr. Mohamed Elkasaby 11100 Euclid Ave Bolwell 5th Floor, Cleveland, OH 44106 University of Kansas Drs. Ryan Townley, Jeff Burns 4350 Shawnee Mission Pkwy Fairway, KS 66205 University of Rochester Drs. Emily Clark, Anton Porsteinsson 919 Westfall Rd Bldg C, Ste 220, Rochester, NY 14618 University of Oklahoma Dr. Claire Delpirou Nouh 920 Stanton L. Young Blvd, Suite 2040 Oklahoma City, OK 73104 University of Toronto Dr. Carmela Tartaglia 399 Bathurst St. WW 5-449 Toronto, ON M5T 2S8 University of Washington Dr. Michael Rosenbloom 325 9th Ave Main Hospital, Seattle, WA 98104 University Texas Health Dr. Paul Schulz 1941 East Road, Suite 4358 Houston, TX 77054 West Virginia University Drs. Joseph Malone, Lauren Bojarski, Marc Haut 33 Medical Center Drive Morgantown, WV 26506 Virginia Commonwealth University Health System Dr. James “Trey” Bateman 417 N 11th St, Richmond, VA 23298

Symptomatic Treatments Obviously the focus of AQI are the AATs. But we can't neglect symptomatic management. Because maximizing patient's health means getting into the weeds, finding the worst aspects of their lives and making them better. We ask you to focus on: AChE-I for memory (not for MCI). Memantine for late disease. Brexpiprazole: FDA approved for agitation. Show a reluctance to use benzos, neuroleptics, and anti-seizure drugs in general for N-psych problems. Demonstrate knowledge about anti-cholinergic danger. Steer families away from quacks and frauds, ie., Prev@gen among many others. Behavioral approaches, caregiver coaching.

We are a group of Alzheimer clinicians interested in improving care for those afflicted with AD, their families, and their doctors.

Safely Implement Anti-Amyloid Treatments Safety concerns for the new anti-amyloid therapies are such that 1) The patients should be made aware of all possible effects of the treatment and 2) Physicians and practitioners should be systematically tracking the administration of the drugs that are interspersed with regularly scheduled MRIs. Any concerns should be brought up immediately, communication is key to the success of these new therapeutics. Anti-amyloid therapies are slowing the progression of Alzheimer's dementia, but they are not without risks. The main risk is amyloid-related imaging abnormalities [ARIAs] which can be brain swelling or microhemorrhages in the brain. Because of the possible risk of ARIAs, steps need to be put in place to carefully monitor and manage the patient's progress with the treatments. There are currently 2 FDA-approved ATTs in the United States: lecanemab (Leqembi; Eisai, Nutley, NJ; accelerated approval January 2023, traditional approval July 2023) and donanemab (Kisunla; Eli Lilly, Indianapolis, IN; approved July 2024). These therapies mark a dramatic pharmacologic change for the treatment of mild cognitive impairment and mild dementia due to AD, and they have different infrastructural requirements. ATTs require a more extensive diagnostic, treatment, and monitoring process and increased participation of health care personnel compared with previous therapies (eg, acetylcholinesterase inhibitors, memantine, neuropsychiatric management). It is crucial that AD be diagnosed and disclosed in a timely manner. Initial clinical visits should focus on the clinical stage of the disease, overall health and comorbid conditions, and caregiver support. Later visits should include discussions with patients based on genetic and imaging findings, evidence of amyloid in cerebrospinal fluid samples or positron emission tomography images, and careful and thoughtful selection for therapy which requires informed patient consent. After beginning ATT therapy, individuals with AD require appropriate MRI monitoring, infusion scheduling, ARIA management, and ongoing discussions with physicians to ensure compliance, expectations, and understanding*. What is your plan to safely administer these drugs? Is it a spreadsheet? Is it an app ? Is it paper? What checklists are in place prior to the first dose? The paradigm shift associated with the emergence of ATTs has created the need for new clinical systems and workflows, interdisciplinary teams, and technical expertise for effective ATT administration. Treating physicians find themselves in various stages of motivation and readiness; however, individuals and families interested in pursuing ATT are often placed on a waiting list. In this article, we describe the components of an optimal ATT program, including workflow, staffing, oversight, and billing considerations; flexibility needs; and troubleshooting pointers. An optimal ATT program can help physicians maximize patient wellbeing, autonomy, and safety. Every program should be built for optimal flow while anticipating potential barriers which could disrupt patient care*. *Weisman, D., & Cabral, D. (2025, July 25). Building an infrastructure to administer amyloid-targeting treatments. Practical Neurology. https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/building-an-infrastructure-to-administer-amyloid-targeting-treatments/36187/

Resources We are providing extra resources to keep you informed about current best practices for Alzheimer's and Dementia treatment. You can download an editable Word Document or a PDF AQI Intake Questions Lecanemab Informed Consent PREVGEN is a Scam Letter to Patients COG Survey Follow Ups to Care Partner Donanemab Informed Consent NEURIVA is a Scam Letter to Patients Intake Survey for Memory Problems Difference Between the Two New Amyloid Therapeutics Cerefolin is a Scam Letter

Certification Benefits AQI can't help patients if we don't help those who help patients. So we pledge to never burden you with admin tasks or distractions. With certification, we encourage centers to display an "AQI Center of Excellence" seal. This is an award to all staff. Please use the accreditation status on public materials and digital platforms. Once AQI welcomes you, we will list you as an AQI center of excellence. You are invited to a webinar about difficult cases.

Copyright Policy Copyright Notice© 2024 Alzheimer’s Quality Initiative, Inc. All rights reserved. Unauthorized use prohibited.Alzheimer’s Quality Initiative copyright materials may not be reproduced in whole or in part by persons, organizations or corporations other than the AQI, its affiliates, divisions and units without the prior written permission of the AQI.The information contained in this Alzheimer’s Quality Initiative (AQI) website is not a substitute for medical advice or treatment, and the AQI recommends consultation with your doctor or health care professional. Copyright and Trademark ViolationsThe Alzheimer’s Quality Initiative takes intellectual property rights seriously. We work diligently to ensure that our works do not infringe on anyone else's rights and that others do not infringe on the AQI ‘s intellectual property rights.Visit the DMCA Notification Guidelines page for more information about how to report a copyright violation

Welcome to the Alzheimer's Quality Initiative Our mission is to improve Alzheimer's disease care. We evaluate, then coach or award based on: - Ability to diagnose and disclose Alzheimer's disease. - Timeline to treatment (Door-to-Needle time). - Number dosed in your community. - Systems for safety, monitoring, and dosing. - Appropriate symptomatic management. We will never interfere with burdensome admin metrics which distract from patient care. Those who do not trust cannot be trusted. Once certified, Alzheimer's Centers of Excellence will share case reports, disseminate ideas, and further improve clinical care. AQI Certified Centers AQI Certified Centers, recognized and certified for providing excellence in Alzheimer's care. 3) Ray Dolby Brain Health Center Sutter Health 45 Castro Street, Suite 220 San Francisco, CA 94114

Accessibility Statement The Alzheimer’s Quality Initiative strives to make our websites accessible. The Alzheimer’s Quality Initiative is committed to diversity, inclusion, and meeting the needs of all our constituents, including those with disabilities. We are continually improving our digital assets to comply with the accessibility guidelines for levels A and AA in accordance with WCAG 2.1.If the format of any material on our web pages interferes with your ability to access the information, please contact us to request assistance or if you have questions or comments about our web sites’ accessibility please call XXXXXXX for assistance.

Refund Policy A legal disclaimer The explanations and information provided on this page are only general and high-level explanations and information on how to write your own document of a Refund Policy. You should not rely on this article as legal advice or as recommendations regarding what you should actually do, because we cannot know in advance what are the specific refund policies that you wish to establish between your business and your customers. We recommend that you seek legal advice to help you understand and to assist you in the creation of your own Refund Policy. Refund Policy - the basics Having said that, a Refund Policy is a legally binding document that is meant to establish the legal relations between you and your customers regarding how and if you will provide them with a refund. Online businesses selling products are sometimes required (depending on local laws and regulations) to present their product return policy and refund policy. In some jurisdictions, this is needed in order to comply with consumer protection laws. It may also help you avoid legal claims from customers that are not satisfied with the products they purchased. What to include in the Refund Policy Generally speaking, a Refund Policy often addresses these types of issues: the timeframe for asking for a refund; will the refund be full or partial; under which conditions will the customer receive a refund; and much, much more.

How Do You Increase The Number Of Treated Alzheimers Patients? Increasing the number of people treated for Alzheimer’s in a community is a systems problem. An Alzheimer Center of Excellence will have adequate resources, less wait times, fast tracks for those interested in AATs, high awareness of the disease state and appropriate therapeutics.